Skip to content

Total debt at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$2.18B+41.7%
Opko Health logo
Opko HealthOPK
$52.78M-4.2%
AptarGroup logo
AptarGroupATR
$1.43B+32.7%
ARS Pharmaceuticals, Inc. logo
ARS Pharmaceuticals, Inc.SPRY
$96.52M+132,122%
Pfizer logo
PfizerPFE
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total equity$445.5M
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$926.83M-19.9%
Enterprise value$1.44B-11.4%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%
Debt / equity0.2×
Current ratio3.9×+0.9×

Where this comes from

Calculated from Amphastar Pharmaceuticals’s reported figures.

Plus components not separately reported this period.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's total debt?
Amphastar Pharmaceuticals (AMPH) reported total debt of $686.61M in Q1 2026.
How has Amphastar Pharmaceuticals's total debt changed year-over-year?
Amphastar Pharmaceuticals's total debt increased by 5.2% year-over-year, from $652.92M to $686.61M.
What is the long-term trend for Amphastar Pharmaceuticals's total debt?
Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's total debt has grown at a 57.5% compound annual growth rate (CAGR), from $67.8M to $656.27M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.